Oncology and Hematology
1643
Episodes 49-64 of 69
- MinuteCE®
Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
1.00 program credit
Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD
Ghassan K. Abou-Alfa, MD
- MinuteCE®
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
1.00 program creditGhassan K. Abou-Alfa, MD
- MinuteCE®
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
1.00 program creditAiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD
Ghassan K. Abou-Alfa, MD
Aiwu Ruth He, MD, PhD
- MinuteCE®
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
1.00 program creditGhassan K. Abou-Alfa, MD
Yelena Janjigian, MD
Samuel J. Klempner, MD
Yelena Janjigian, MD
Samuel J. Klempner, MD
Yelena Janjigian, MD
Samuel J. Klempner, MD
Yelena Janjigian, MD
Samuel J. Klempner, MD
